DK0977555T3 - Farmaceutiske præparater og fremgangsmåder til deres regionale indgivelse - Google Patents

Farmaceutiske præparater og fremgangsmåder til deres regionale indgivelse

Info

Publication number
DK0977555T3
DK0977555T3 DK98902614T DK98902614T DK0977555T3 DK 0977555 T3 DK0977555 T3 DK 0977555T3 DK 98902614 T DK98902614 T DK 98902614T DK 98902614 T DK98902614 T DK 98902614T DK 0977555 T3 DK0977555 T3 DK 0977555T3
Authority
DK
Denmark
Prior art keywords
drug
region
excipient
formulations
methods
Prior art date
Application number
DK98902614T
Other languages
Danish (da)
English (en)
Inventor
Vanaja V Ragavan
Gerianne M Dipiano
Original Assignee
Femmepharma Holding Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27365086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0977555(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Femmepharma Holding Co Inc filed Critical Femmepharma Holding Co Inc
Application granted granted Critical
Publication of DK0977555T3 publication Critical patent/DK0977555T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98902614T 1997-01-24 1998-01-23 Farmaceutiske præparater og fremgangsmåder til deres regionale indgivelse DK0977555T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672797P 1997-01-24 1997-01-24
US5257897P 1997-07-15 1997-07-15
US08/971,346 US5993856A (en) 1997-01-24 1997-11-17 Pharmaceutical preparations and methods for their administration

Publications (1)

Publication Number Publication Date
DK0977555T3 true DK0977555T3 (da) 2006-07-10

Family

ID=27365086

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98902614T DK0977555T3 (da) 1997-01-24 1998-01-23 Farmaceutiske præparater og fremgangsmåder til deres regionale indgivelse

Country Status (11)

Country Link
US (1) US5993856A (cg-RX-API-DMAC7.html)
EP (2) EP0977555B1 (cg-RX-API-DMAC7.html)
JP (2) JP2001511773A (cg-RX-API-DMAC7.html)
AT (1) ATE321532T1 (cg-RX-API-DMAC7.html)
AU (1) AU743157B2 (cg-RX-API-DMAC7.html)
CA (1) CA2278541C (cg-RX-API-DMAC7.html)
DE (1) DE69834025T2 (cg-RX-API-DMAC7.html)
DK (1) DK0977555T3 (cg-RX-API-DMAC7.html)
ES (1) ES2260828T3 (cg-RX-API-DMAC7.html)
PT (1) PT977555E (cg-RX-API-DMAC7.html)
WO (1) WO1998032422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
WO1999060938A1 (en) 1998-05-23 1999-12-02 Focal, Inc. Method of treatment for premature rupture of membranes in pregnancy (prom)
US20070178139A1 (en) * 1998-11-18 2007-08-02 Yankov Vladimir I Vaginally administratable progesterone-containing tablets and method for preparing same
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6350464B1 (en) 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537566B1 (en) 1999-03-11 2003-03-25 John Alton Copland Compositions and methods for the non-invasive treatment of uterine fibroid cells
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
AU6124401A (en) * 2000-05-09 2001-11-20 Nitromed Inc Infrared thermography and methods of use
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002020663A2 (en) 2000-09-06 2002-03-14 Ap Pharma, Inc. Degradable polyacetal polymers
AU2002211840A1 (en) 2000-10-02 2002-04-15 Kimberly-Clark Worldwide, Inc. Nanoparticle based inks and methods of making the same
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same
AU2002354957A1 (en) * 2001-07-19 2003-03-03 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
AU2002366800B2 (en) * 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004022100A1 (en) * 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
US6780896B2 (en) 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
AU2007216882B2 (en) * 2003-01-02 2010-03-11 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatment of diseases and disorders of the breast
US9173836B2 (en) * 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
JP2004323454A (ja) * 2003-04-25 2004-11-18 Chisso Corp 薬剤
AU2004267956B2 (en) * 2003-09-03 2010-09-16 Miscon Trading S.A. Methods for the treatment of endometriosis
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
WO2005027807A1 (en) 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US7919453B2 (en) 2005-03-25 2011-04-05 Kimberly-Clark Worldwide, Inc. Dosage cap assembly for an applicator
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
US7744556B2 (en) 2005-03-25 2010-06-29 Kimberly-Clark Worldwide, Inc. Delivery tube assembly for an applicator
US7527614B2 (en) 2005-03-25 2009-05-05 Kimberly-Clark Worldwide, Inc. Protective tube for a medicated tampon
US7708726B2 (en) 2005-04-28 2010-05-04 Kimberly-Clark Worldwide, Inc. Dosage form cap for an applicator
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
EP2462959B1 (en) * 2005-07-12 2016-06-22 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
WO2007079389A2 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US8080540B2 (en) * 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
RU2327459C1 (ru) * 2007-06-26 2008-06-27 Евгений Сергеевич Северин Лекарственное средство противомикробного действия, способ получения лекарственного препарата направленного действия, содержащего наночастицы
WO2009073782A2 (en) * 2007-12-04 2009-06-11 Ams Research Corporation Apparatus and methods for treatment of pathologic proliferative conditions of uterine tissue
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
JP2012512163A (ja) * 2008-12-11 2012-05-31 エーピー ファーマ, インコーポレイテッド ポリオルトエステルおよびそれらの製剤の安定性を高めるための方法
US9504274B2 (en) * 2009-01-27 2016-11-29 Frito-Lay North America, Inc. Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
SG177302A1 (en) * 2009-06-22 2012-02-28 Dmi Acquisition Corp Methods and products for treatment of diseases
SG2014008171A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
WO2011006067A1 (en) * 2009-07-09 2011-01-13 Ams Research Corporation Apparatus and methods of treatment of pathologic proliferative conditions uterine tissue
US20110033545A1 (en) * 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG11201504380SA (en) 2012-12-19 2015-07-30 Ampio Pharmaceuticals Inc Method for treatment of diseases
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
WO2016004960A2 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
IL271596B2 (en) * 2017-06-22 2024-07-01 Viramal Ltd Emulsion compositions comprising danazol for use in the treatment of an endometrial disease or condition
AU2019365255B2 (en) 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4081533A (en) * 1976-09-01 1978-03-28 Regents Of The University Of California Method of reducing mammalian fertility and drugs therefor
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4291028A (en) * 1977-12-30 1981-09-22 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4286587A (en) * 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
BE879442A (fr) * 1978-10-17 1980-04-16 Stolle Res And Dev Corp Microparticules contenant des agents therapeutiques ou medicinaux et leur application comme contraceptif
DE3214667C2 (de) * 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4591496A (en) * 1984-01-16 1986-05-27 Massachusetts Institute Of Technology Process for making systems for the controlled release of macromolecules
NL8401912A (nl) * 1984-06-15 1986-01-02 Tno Met aktieve stof beladen biodegradeerbare polymeersubstraten, geschikt voor het gecontroleerd afgeven van de aktieve stof door middel van een membraan.
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5057317A (en) * 1987-03-24 1991-10-15 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4873092A (en) * 1987-05-21 1989-10-10 Murata Kikai Kabushiki Kaisha Slow-releasing preparation
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JP2927830B2 (ja) * 1989-09-01 1999-07-28 東京田辺製薬株式会社 ダナゾール坐剤
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5156851A (en) * 1990-06-20 1992-10-20 Monsanto Company Coated veterinary implants
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1992014449A1 (en) * 1991-02-20 1992-09-03 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
DK0501656T3 (da) * 1991-02-21 1997-07-21 Sankyo Co Benzenderivater med en fremskyndende aktivitet på produktion af nervevækstfaktor
JPH0735335B2 (ja) * 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
ES2115638T3 (es) * 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
WO1993017668A1 (en) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5651976A (en) * 1993-06-17 1997-07-29 The United States Of America As Represented By The Secretary Of The Navy Controlled release of active agents using inorganic tubules
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
NL9400410A (nl) * 1994-03-16 1995-11-01 M D Ph D Willem Arthur Adriaan Intra-uterine anticonceptiemiddel.
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.

Also Published As

Publication number Publication date
CA2278541C (en) 2006-10-24
JP2001511773A (ja) 2001-08-14
DE69834025T2 (de) 2006-11-09
EP2316424A1 (en) 2011-05-04
PT977555E (pt) 2006-06-30
ES2260828T3 (es) 2006-11-01
AU743157B2 (en) 2002-01-17
JP2010138196A (ja) 2010-06-24
AU5922798A (en) 1998-08-18
US5993856A (en) 1999-11-30
DE69834025D1 (de) 2006-05-18
WO1998032422A1 (en) 1998-07-30
ATE321532T1 (de) 2006-04-15
EP0977555B1 (en) 2006-03-29
CA2278541A1 (en) 1998-07-30
EP0977555A1 (en) 2000-02-09

Similar Documents

Publication Publication Date Title
PT977555E (pt) Preparacoes farmaceuticas e metodos para a sua administracao localmente
DE69940015D1 (de) Pharmazeutische zubereitungen enthaltend einen amphoteren emulgator, polyproxylierten cetylalkohol und einen polaren wirkstoff
BR0212475A (pt) Composições farmacêuticas
AU4261097A (en) Compositions and methods for topical application of therapeutic agents
CA2416383A1 (en) Solution-, dispersion- or emulsion-producing film dermatics
WO2000015245A3 (en) Stable liquid formulations of botulinum toxin
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
PT1121144E (pt) Preparados de insulina concentrada estavel para administracao pulmonar
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
WO2001087227A3 (en) Drug containing polymeric micelles
DK157689A (da) Farmaceutiske piroxicammidler i vandige oploesninger samt fremgangsmaade til fremstilling heraf
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
WO2004066983A3 (en) Controlled release of highly soluble agents
WO2001072264A3 (de) Pro-liposomal verkapselte zubereitungen (iv)
WO2000010533A3 (en) Compositions and methods for treating intracellular infections
DE59811768D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
ZA97596B (en) Solid instant-release forms of administration and processes for their production
WO2002000208A3 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
ATE177638T1 (de) Topisch anzuwendendes arzneimittel enthaltend penciclovir